Considered before DOTATATE (Q1) | Intended after DOTATATE (Q2) | Final implemented management (Q3) | Reason for nonimplementation |
Surgery | → CTx/other | → CTx | Tumor board/final medical decision |
Surgery | → w/w | → Surgery | Tumor board/final medical decision |
w/w | → Surgery | → Octreotide/other | Tumor board/final medical decision |
CTx/PRRT | → CTx | → XRT/other | Tumor board/final medical decision |
CTx/PRRT | → PRRT | → CTx/PRRT | Tumor board/final medical decision |
CTx/PRRT/octreotide/other | → CTx/PRRT/octreotide/other | → Surgery/CTx/octreotide | Tumor board/final medical decision |
XRT | → XRT | → Surgery/CTx | Tumor board/final medical decision |
PRRT | → PRRT | → Octreotide | Tumor board/final medical decision |
PRRT/octreotide | → PRRT/octreotide | → CTX/octreotide | Tumor board/final medical decision |
Surgery | → Surgery | → Surgery/other | Tumor board/final medical decision |
Surgery/octreotide | → Surgery | → Octreotide/w/w | Second opinion in another institution |
Octreotide | → Octreotide | → PRRT | Second opinion in another institution |
Surgery/XRT/w/w | → XRT | → w/w | Patient decision/travel |
CTx | → PRRT | → CTX/octreotide | Financial issue |
Surgery | → w/w | Unknown | Lost to follow-up |
CTx/XRT/octreotide | → CTx/other | Unknown | Lost to follow-up |
Other | → Other | Unknown | Lost to follow-up |
Other | → Octreotide/other | Unknown | Unknown |
Octreotide/w/w | → Surgery/octreotide/w/w | Unknown | Unknown |
Surgery | → Surgery | Unknown | Unknown |
w/w | → w/w | Unknown | Unknown |
DOTATATE = 68Ga-DOTATATE PET/CT; CTx = chemotherapy; XRT = external-beam radiotherapy; PRRT= peptide receptor radionuclide therapy; w/w = watch and wait.